Véronique A. Cornelissen

Complementary and alternative medicine · 2005–2023

A researcher in the Science corpus: 4 papers; trusts 2 researchers and is trusted by 2 researchers here, as inferred from the citation graph.

Subfields

Whom Véronique A. Cornelissen trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Catherine Sherrington

Who trusts Véronique A. Cornelissen overall

  1. B. K. Pedersen
  2. B. Saltin

Papers from Véronique A. Cornelissen's perspective

Ordered by how strongly the researchers Véronique A. Cornelissen trusts endorse each paper. Same corpus, a different order for every researcher.

  1. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 ‡ (European Journal of Heart Failure)
  2. Home-based versus centre-based cardiac rehabilitation (Cochrane Database of Systematic Reviews)
  3. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular… (European Journal of Cardiovascular Prevention & Rehabilitation)
  4. Frailty Assessment in the Cardiovascular Care of Older Adults (Journal of the American College of Cardiology)
  5. Commentary: The new ESC guidelines for the diagnosis and management of chronic coronary syndromes. (International Journal of Cardiology)
  6. Exercise management in type 1 diabetes: a consensus statement. (The Lancet Diabetes and Endocrinology)
  7. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. (Journal of the American Medical Association (JAMA))
  8. Evidence for physiotherapy practice: a survey of the Physiotherapy Evidence Database (PEDro). (Australian Journal of Physiotherapy)
  9. Fifth INTERMACS annual report: risk factor analysis from more than 6,000 mechanical circulatory support patients. (The Journal of Heart and Lung Transplantation)
  10. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. (New England Journal of Medicine)

Their papers